Editorial Comment: A Variable Length Biopsy Device Designed for Improved Prostate Cancer Detection vs the Standard Biopsy Device: Pathological Comparisons and Needle Length Requirements for Men Undergoing Transperineal Biopsy

This study of a length-adjustable biopsy device draws attention to an underexplored aspect of prostate cancer (PCa) diagnostics.1 While elegant engineering of the Triopsy device achieves longer and intact cores with higher notch yield compared with a conventional device, the critical question remains—will longer cores translate into increased detection of clinically significant PCa? For decades, the biopsy needle has remained essentially unchanged, limited to retrieving cores of ∼1.9 cm. Mapping analysis in this study suggested that nearly 80% of planned transperineal biopsy trajectories exceed this length, highlighting a mismatch between anatomy and device capability.1 Studies, largely from the pre-MRI era, support the notion that increased core length may mitigate undergrading.2,3 Thus, it is important to understand if longer and intact cores can reduce biopsy/prostatectomy pathological discordance and the frequency of upgrading in active surveillance cohorts or help accurately characterize tumours for focal therapy. This study relied on porcine models and mapping software rather than men undergoing MRI-targeted biopsy.1 Whether a 5.5-cm core improves detection of clinically significant PCa without inflating the diagnosis of indolent Gleason 6 disease remains unknown. Longer strokes can inevitably increase inadvertent contact with adjacent structures such as the bladder and neurovascular bundle injury increasing rates of bleeding, urinary retention, and erectile dysfunction and needs evaluation. In the era of MRI-fusion, where lesions-directed and perilesional sampling already enhances yield, the incremental benefit of traversing the gland with longer cores is uncertain. Yet, it is important to recognize that these strategies were developed in the era of fixed-length needles. As practice shifts toward MRI-fusion guided and personalized approaches, device design must evolve in parallel. A system capable of retrieving longer cores may reduce puncture burden and enhance histological adequacy, but these benefits require clinical validation. Until then, the promise of longer, intact cores remain compelling but unproven.